Pressure Ulcer, Stage IVPhase 2BLADE OPU2NCT06283979
A Randomized Controlled Phase II Trial of STIMULAN VG vs Standard of Care (SoC) for the Treatment of Osteomyelitis Associated With Stage IV Pressure Ulcers.
A Phase 2 study testing STIMULAN VG in people with Pressure Ulcer, Stage IV and Osteomyelitis, run by Biocomposites Ltd at 9 sites in United States.
Trial summary
The purpose of this trial is to assess the safety, tolerability and between-group effect size of STIMULAN VG (with debridement) and a course of systemic antibiotics to standard of care (debridement and systemic antibiotics only) for the treatment of osteomyelitis associated stage IV pressure ulcers. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Pressure Ulcer, Stage IV, Osteomyelitis
- What is being tested?
- STIMULAN VG
- Type of treatment
- Surgery or procedure
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 60 participants
- Where
- 9 sitesUnited States
- Study dates
- 15 Jun 2025to 1 Dec 2026
- Phase
- Phase 2
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
In order to be eligible to participate in this study, subjects must meet all of the following criteria:
- Presenting with a Stage IV pressure ulcer requiring treatment of excision, bony debridement and flap coverage/primary closure.
- Operative candidate for flap surgery or primary closure.
- Presence of focal osteomyelitis as suggested by imaging to show extent of infection. Acceptable imaging techniques are Magnetic Resonance Imaging or CT scan.
- Adults ≥ 18 years in age at the time of treatment.
- Psychosocially, mentally, and physically able to fully comply with this protocol, including adhering to scheduled visits, treatment plan, completing forms, and other study procedures.
- Ability of the subject or legal authorized representative to provide voluntary, signed and dated informed consent prior to any study-related procedures.
Subjects who meet any of the following criteria will be excluded from participating in this study:
- Reasons contributing to pressure ulcer cannot be addressed.
- Severe immunological compromised patients as determined by the clinician.
- Patients with diffuse or widespread pelvic osteomyelitis that is not amenable to adequate margins for debridement.
- Patients presenting with head pressure ulcers.
- Current or recent history (within last 2 years) of active substance abuse (e.g., recreational drugs, narcotics, or alcohol) that in the judgement of the investigator, may compromise the participant's safety/recovery or ability to follow the trial procedures.
- Current smoker.
- Diabetic patient with Hba1C level above 9.
- Allergy to any component of the investigational product, such as calcium sulfate, glycopeptide antibiotics (Vancomycin), or aminoglycoside antibiotics (Gentamicin).
- Concurrent involvement in a study of another investigational product.
- Pregnant or planning to become pregnant during study period.
- Flexion contractures where patient cannot passively get full extension.
- Uncontrolled muscle spasms.
- Unable to comply with bedrest restriction or offloading requirements
- Unable to provide consent.
- Fecal or urinary incontinence with contamination of the wound.
- Lower extremity pressure ulcer location that is vascularly compromised as defined by an Ankle Brachial Index ≤ 0.7 mm Hg OR toe brachial index ≤ 0.6 mm OR toe pressure ≤ 40 mm Hg OR transcutaneous oximetry ≤ 40 mm Hg *
- Investigator considers the participant to be clinically malnourished.
- Any conditions with known hypercalcemia (> 10.3 mg/dl) or posing a significant risk for developing hypercalcemia (i.e., Hyperparathyroidism).
- Investigator believes trial participation may compromise safety of the participant or trial results.
- Patients presenting with lower extremity pressure ulcers that are vascularly compromised can be rescreened followed successful revascularization
Trial locations and contacts
9 sites in 1 country. Contact the study team or a site near you to ask about taking part.
Daniel Roberts contact
9 sites in 1 country
United States9 sites, 9 recruiting
- Recruiting
Northwestern University Feinberg School of Medicine
Chicago, Illinois, 60611
Brigid Coles, 312-503-3209, brigid.coles@nm.org
Tarifa Adam, 312-503-3209, tarifa.adam@nm.org
- Recruiting
Missouri Orthopaedic Institute
Columbia, Missouri, 65201
Andrew Monhollen, am5hf@health.missouri.edu
Vicki Jones, jonesvicki@health.missouri.edu
- Recruiting
Henry Ford Hospital
Detroit, Michigan, 48202
Dan Molitor, dmolito2@hfhs.org
Sarah Meehan, smeehan1@hfhs.org
- Recruiting
University of Mississippi Medical Center
Jackson, Mississippi, 39216
Venkata Seerapu, vseerapu@umc.edu
Laxmi Dhungel, idhungel@umc.edu
- Recruiting
NYU Langone Hospital - Long Island Clinical Research Center
Mineola, New York, 11501
Anita Farha, 516 663 9582, anita.farhi@nyulangone.org
Monica Benitez, 516 663 9582, monica.benitez@nyulangone.org
- Recruiting
Rutgers New Jersey Medical School
Newark, New Jersey, 07103
Saharsh Patel, ssp186@gsbs.rutgers.edu
Mehreen Bhatti, mb2276@njms.rutgers.edu
- Recruiting
University of Nebraska Medical Center
Omaha, Nebraska, 68198
Katie Ostlund, katie.ostlund@unmc.edu
Gabriel Gauthier, gabriel.gauthier@unmc.edu
- Recruiting
Advanced Foot Care, LLC
Phoenix, Arizona, 85032
Krishna Sai Penumarthi, (480) 863-6044, kspenumarthi@axentrabio.com
Rajashekhar Ittedi, (480) 863-6044, rajaittedi123@gmail.com)
- Recruiting
University of Pittsburgh, McGowan Institute for Regenerative Medicine
Pittsburgh, Pennsylvania, 15219
Urmila Gnyawali, 412-624-5500, usg2@pitt.edu
Scot King, 412-624-5500, scot.king@pitt.edu
About this study
Official title: A Multi-center, Randomized (1:1), Controlled Phase II Trial of STIMULAN VG With Debridement and a Course of Systemic Antibiotics vs Standard of Care (SoC) for the Treatment of Osteomyelitis Associated With Stage IV Pressure Ulcers.
The purpose of this trial is to assess the safety, tolerability and between-group effect size of STIMULAN VG (with debridement) and a course of systemic antibiotics to standard of care (debridement and systemic antibiotics only) for the treatment of osteomyelitis associated stage IV pressure ulcers.
Read the detailed description
The trial is an open-label, multi-center, randomized (1:1), controlled phase 2 trial in patients diagnosed with stage IV pressure ulcers.
- Conditions
- Pressure Ulcer, Stage IV, Osteomyelitis
- Being tested
- STIMULAN VG, Standard of Care
- Keywords
- between-group effect size, surgical debridement, ulcer bursectomy, systemic antibiotics
- Medical subject headings
- Pressure Ulcer, Osteomyelitis
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
STIMULAN VGCombination product
Insertion of STIMULAN VG into the ulcer cavity prior to flap/primary closure.
Standard of CareProcedure or surgery
Standard of Care. Ulcer bursectomy, debridement and flap/primary closure. Peri-operative antibiotics.
| Study group | Role | What they receive |
|---|---|---|
| Interventional STIMULAN VG | Experimental | Ulcer bursectomy and debridement and STIMULAN VG insertion into the ulcer cavity.
Flap/primary closure. Peri-operative antibiotics. Receives: Combination Product: STIMULAN VG; Procedure: Standard of Care |
| Standard of Care (SoC) | Active comparator | Ulcer bursectomy, debridement and flap/primary closure. Peri-operative antibiotics. Receives: Procedure: Standard of Care |
What is being measured
The primary outcome is the main question the study is designed to answer.
Individual patient success and findings at the 8 week follow-up visit
An individual patient treatment will be considered a success if there is complete wound closure and healing at the surgical site at two consecutive visits 2 weeks apart.
Measured: 8 week
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted28 Feb 2024
- Study start15 Jun 2025
- Primary completion1 Dec 2026 (estimated)
- Study completion1 Dec 2026 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Pressure Ulcer, Stage IVStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 2
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Enrolment
- 60 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Biocomposites Ltd
- Sponsor type
- Industry (pharma, biotech, devices)
- Collaborators
- MCRA
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06283979
- Sponsor's protocol ID
- 199723
- Acronym
- BLADE OPU2
- Status last verified
- Oct 2025
- First submitted
- 21 Feb 2024
- Last updated
- 6 May 2026
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- Yes
- FDA-regulated device
- No
- Individual data sharing
- No
- Expanded access
- Available
Study at a glance
From the registry record, last updated by the sponsor on 6 May 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Multi-center, Randomized (1:1), Controlled Phase II Trial of STIMULAN VG With Debridement and a Course of Systemic Antibiotics vs Standard of Care (SoC) for the Treatment of Osteomyelitis Associated With Stage IV Pressure Ulcers.
- ClinicalTrials.gov ID
- NCT06283979
- Acronym / sponsor ID
- BLADE OPU2 / 199723
- Conditions
- Pressure Ulcer, Stage IV, Osteomyelitis
- Keywords
- between-group effect size, surgical debridement, ulcer bursectomy, systemic antibiotics
- Phase
- Phase 2
- Study type
- Interventional
- Recruitment status
- Recruiting
- Enrolment
- 60 participants (estimated)
- Lead sponsor
- Biocomposites LtdIndustry (pharma, biotech, devices)
- Collaborators
- MCRA
- Study start
- 15 Jun 2025 (actual)
- Primary completion
- 1 Dec 2026 (estimated)
- Study completion
- 1 Dec 2026 (estimated)
- First posted
- 28 Feb 2024 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The purpose of this trial is to assess the safety, tolerability and between-group effect size of STIMULAN VG (with debridement) and a course of systemic antibiotics to standard of care (debridement and systemic antibiotics only) for the treatment of osteomyelitis associated stage IV pressure ulcers.
Detailed description
The trial is an open-label, multi-center, randomized (1:1), controlled phase 2 trial in patients diagnosed with stage IV pressure ulcers.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Interventional STIMULAN VG | Experimental | Combination Product: STIMULAN VG, Procedure: Standard of CareUlcer bursectomy and debridement and STIMULAN VG insertion into the ulcer cavity. Flap/primary closure. Peri-operative antibiotics. |
| Standard of Care (SoC) | Active comparator | Procedure: Standard of CareUlcer bursectomy, debridement and flap/primary closure. Peri-operative antibiotics. |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| STIMULAN VGInsertion of STIMULAN VG into the ulcer cavity prior to flap/primary closure. | Combination product | Interventional STIMULAN VG |
| Standard of CareStandard of Care. Ulcer bursectomy, debridement and flap/primary closure. Peri-operative antibiotics. | Procedure or surgery | Interventional STIMULAN VG, Standard of Care (SoC) |
Primary outcome
Individual patient success and findings at the 8 week follow-up visit
Time frame: 8 week
An individual patient treatment will be considered a success if there is complete wound closure and healing at the surgical site at two consecutive visits 2 weeks apart.
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 6 May 2026.
- Individual participant dataSharing planned: No
Related trials for Pressure Ulcer, Stage IV
Recruiting
Comparison of Transforming Powder Dressing to NPIAP Recommended Standard of Care Therapies in Stage 2, 3 and 4 Pressure Injuries
Pressure Ulcers Stage II, Pressure Ulcers Stage III
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Daniel Roberts contact
9 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 2 study testing STIMULAN VG in people with Pressure Ulcer, Stage IV and Osteomyelitis, run by Biocomposites Ltd at 9 sites in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 6 May 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 9 sites in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Keira Watts, Clinical Research Director (+44 (0) 1782 338 580, clinicaltrials@biocomposites.com), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Individual patient success and findings at the 8 week follow-up visit (time frame: 8 week). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 6 May 2026.